MedPath

CARsgen Partners with Zhuhai SB Xinchuang to Advance Allogeneic CAR-T Development in China

• CARsgen Therapeutics has partnered with Zhuhai SB Xinchuang, securing RMB 80 million investment for its subsidiary UCARsgen to develop allogeneic CAR-T cell therapies in mainland China.

• The agreement grants UCARsgen exclusive rights to develop BCMA-targeted therapy for multiple myeloma and CD19/CD20 dual-targeted therapy for B-cell malignancies.

• Following the investment, CARsgen will retain 92% ownership of UCARsgen, with Zhuhai SB Xinchuang holding an 8% equity stake in the venture.

CARsgen Therapeutics Holdings Limited has formed a strategic partnership with Zhuhai SB Xinchuang to accelerate the development of innovative allogeneic CAR-T cell therapies in mainland China. The collaboration, announced through a series of agreements, centers on UCARsgen Biotech Limited, CARsgen's subsidiary focused on allogeneic CAR-T cell therapy development.

Strategic Investment and Rights Transfer

Under the agreements, an investment fund managed by Zhuhai SB Xinchuang will invest RMB 80 million into UCARsgen, acquiring an 8% equity stake in the company. CARsgen Therapeutics will maintain majority control with a 92% ownership position, down from its previous 100% stake.
The deal includes the transfer of exclusive rights to UCARsgen for mainland China operations, encompassing research, development, manufacturing, and commercialization of two key allogeneic CAR-T products:
  • A BCMA-targeted allogeneic CAR-T cell therapy for multiple myeloma and plasma cell leukemia
  • A CD19/CD20 dual-targeted allogeneic CAR-T cell therapy for B-cell malignancies

Advancing CAR-T Innovation

CARsgen Therapeutics brings significant expertise to this venture, operating a comprehensive CAR T-cell research and development platform that spans from target discovery to commercial-scale production. The company has established operations in both China and the United States, developing novel technologies to address current CAR T-cell therapy challenges.
These innovations focus on critical areas including:
  • Enhancing safety profiles
  • Improving efficacy in solid tumor treatment
  • Reducing treatment costs

Market Impact and Future Prospects

This partnership represents a significant step forward in making advanced cell therapies more accessible in the Chinese market. The focus on allogeneic CAR-T cell therapies could potentially address key limitations of current autologous CAR-T treatments, including manufacturing time and cost constraints.
The collaboration aligns with CARsgen's mission to develop innovative and differentiated cell therapies for cancer patients globally, furthering their goal of making cancer more treatable through advanced cellular therapeutics.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

AstraZeneca Acquires FibroGen China for $160 Million, Strengthening Roxadustat Position

FibroGen has agreed to sell its China subsidiary to AstraZeneca for approximately $160 million, comprising $85 million in enterprise value plus an estimated $75 million in net cash holdings.
The strategic sale will extend FibroGen's cash runway into 2027 and enable continued development of its oncology pipeline, including the Phase 2 trial of FG-3246 for metastatic prostate cancer.

TG Therapeutics Partners with MaxCyte to Advance Novel CAR T-Cell Therapy for Progressive MS

TG Therapeutics has secured access to MaxCyte's flow electroporation technology to develop azercabtagene zapreleucel, an off-the-shelf CAR T-cell therapy for progressive multiple sclerosis.
The Phase 1 clinical trial will evaluate azer-cel in up to 32 patients with progressive MS forms, focusing on determining optimal dosing and safety profiles.

CARsgen's THANK-u Plus Platform Drives Advancements in Allogeneic CAR-T Therapy for Hematologic Malignancies

CARsgen's KJ-C2219, an allogeneic CAR-T therapy targeting CD19/CD20, has been administered to the first patient in an investigator-initiated trial for R/R B-NHL.
A patient with relapsed/refractory multiple myeloma achieved stringent complete response and MRD negativity at day 28 following treatment with CARsgen's BCMA CAR-T therapy.

China's Biopharmaceutical Sector Achieves Record Technology Exports and FDA Approvals

Chinese pharmaceutical companies saw technology exports nearly double in 2023, reaching a record high of 80 cases, signaling growing global influence.
FDA approved Junshi Biosciences' Toripalimab for nasopharyngeal cancer and Bio-Thera Solutions' Avitinib, highlighting recognition of Chinese therapies.

China's NMPA Accepts Aficamten for Obstructive Hypertrophic Cardiomyopathy

China's National Medical Products Administration (NMPA) has accepted the new drug application for Aficamten, a treatment for obstructive hypertrophic cardiomyopathy (oHCM).
Aficamten targets the underlying cause of oHCM, a genetic heart condition affecting an estimated 130,000 to 330,000 individuals in China.

China's NMPA Accepts Aficamten for Obstructive Hypertrophic Cardiomyopathy

Corxel Pharmaceuticals' Aficamten new drug application has been accepted by China's National Medical Products Administration (NMPA).
Aficamten targets obstructive hypertrophic cardiomyopathy (HCM), a genetic heart condition affecting 130,000-330,000 individuals in China.

Shanghai Chest Hospital to Initiate CAR-T Therapy Trial for Lung Cancer

Shanghai Chest Hospital will begin a clinical trial in January to assess a novel CAR-T cell therapy for lung cancer, aiming to enroll 20 patients in the first phase.
The trial leverages CAR-T, an immunotherapy that reprograms a patient's immune cells to target and combat their specific cancer.

Harvard Apparatus Regenerative Technology Partners with Capital Institute of Pediatrics for Esophageal Atresia Treatment

Harvard Apparatus Regenerative Technology (HRGN) collaborates with the Capital Institute of Pediatrics in Beijing to advance treatments for Esophageal Atresia (EA).
The partnership will focus on conducting Investigator Initiated Trials (IITs) to assess the safety and efficacy of HRGN's Cellspan Esophageal Implant (CEI).

CAR-T Therapies Gain Ground in China and Beyond: Regulatory Approvals and Clinical Advancements

Legend Biotech's Carvykti (cilta-cel) receives approval in China for relapsed or refractory multiple myeloma after multiple lines of prior therapy.
JW Therapeutics' Carteyva (relma-cel) gains approval in China for treating relapsed or refractory mantle cell lymphoma in adult patients.

J&J Expands Cell Therapy Portfolio with New CAR-T Deals

Johnson & Johnson has secured rights to two experimental cell therapies for blood cancer, aiming to build on its success in CAR-T treatment development. The deal with Cellular Biomedicine Group involves a $245 million upfront payment for access to therapies showing promise in early-phase trials for recurrent diffuse large B cell lymphoma.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy